Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again
      1. South Africa/
      2. Our innovation /
      3. Focus areas /
      4. Pulmonary Hypertension (PH)

      Pulmonary Hypertension (PH)

      We understand the ways in which pulmonary hypertension (PH) can impair daily life, and are committed to helping to improve understanding and speedy diagnoses of this group of conditions within the medical profession. We are here to help those affected by PH to lead a full life and receive optimal treatment at the right time.
      Female doctor with digital tablet talking with senior male patient in examination room
      Understanding pulmonary hypertension
      PH is a serious and progressive disease with various causes and no cure. [1],[2] There are five groups of PH, as defined by the World Health Organization (WHO). All are severe diseases characterised by high blood pressure in the lungs.[1] Our focus has been on a specific, rare form of PH (WHO Group 1) called pulmonary arterial hypertension (PAH), but our research covers all groups of PH.[1]
      Friends laughing at backyard barbecue
      Our goal is to give people with PH a full life
      At Johnson & Johnson, we are spearheading a new era for PH, working to transform the disease into a long-term manageable condition, so that patients can live a full life. Supported by Actelion’s 20-year heritage of pioneering innovation, we are working to reach more patients and aim to help tackle the diagnosis gap that is delaying access to the care that patients need.
      We want to use our full range of resources to tackle PH. From investment in research and development of new therapies to innovation in medical devices and screening solutions, our commitment to improving outcomes end-to-end along patient pathways is real. We're focused not only on how we treat PH but on a broader spectrum of goals for the PH community. That includes enhancing patient care, as well as advocating and educating to facilitate faster diagnosis.
      JJIM Images/JJMT_Photo_SurgeonPrep_06_1236.jpg
      Our focus on PAH
      PAH (WHO Group 1) is a rare, progressive and relentless disease, where the pressure in the blood vessels of the lungs is elevated, resulting in stress on the heart. [1]

      Despite recent advances, PAH remains a severely debilitating condition that leads to heart disease and early death.[3], [4] Early diagnosis and treatment are critical to helping improve life expectancy,[5] but PAH is difficult to diagnose and there is currently no cure.[2]
      We’re working to transform PAH into a long-term, manageable condition so patients can lead a full life. Johnson & Johnson's aim is to increase the mainstream awareness around PAH so that no patient goes undiagnosed and there’s no delay in diagnosis.
      The PAH Patient Charter
      Our PAH Charter, co-created with the patient community and launched in 2019, outlines what we think patients with PAH should expect from their healthcare.
      Read more

      References:

      [1] Humbert M, , et al 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022; 43(38):3618–3731.
      [2] Pulmonary Hypertension Association. About PH. Available at
      phassociation.org/patients/aboutph/. Accessed October 2022.
      [3] Vachiéry JL, Gaine S. Challenges in the diagnosis and treatment of pulmonary arterial hypertension. Eur Respir Rev 2012; 21:313-20.
      [4] Armstrong I, et al. The patient experience of pulmonary hypertension: a large cross sectional study of UK patients. BMC Pulm Med 2019; 19:67. https://doi.org/10.1186/s12890-019-0827-5.
      [5] Brown LM, et al. Delay in recognition of pulmonary arterial hypertension. Factors identified from the REVEAL registry. Chest 2011; 140(1):19-26.

      CP-497733 | January 2025